Literature DB >> 21807797

Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop.

Clifton O Bingham1, Rieke Alten, Susan J Bartlett, Vivian P Bykerk, Peter M Brooks, Ernest Choy, Robin Christensen, Daniel E Furst, Sarah E Hewlett, Amye Leong, James E May, Pam Montie, Christof Pohl, Tessa C Sanderson, Vibeke Strand, Thasia G Woodworth.   

Abstract

BACKGROUND: While disease flares in rheumatoid arthritis (RA) are a recognized aspect of the disease process, there is limited formative research to describe them.
METHODS: The Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA Flare Definition Working Group is conducting an international research project to understand the specific characteristics and impact of episodic disease worsening, or "flare," so that outcome measures can be developed or modified to reflect this uncommonly measured, but very real and sometimes disabling RA disease feature. Patient research partners provided critical insights into the multidimensional nature of flare. The perspectives of patients and healthcare and research professionals are being integrated to ensure that any outcome measurement to detect flares fulfills the first OMERACT criteria of Truth. Through an iterative data-driven Delphi process, a preliminary list of key domains has been identified to evaluate flare.
RESULTS: At OMERACT 10, consensus was achieved identifying features of flare in addition to the existing core set for RA, including fatigue, stiffness, symptom persistence, systemic features, and participation. Patient self-report of flare was identified as a component of the research agenda needed to establish criterion validity for a flare definition; this can be used in prospective studies to further evaluate the Discrimination and Feasibility components of the OMERACT filter for a flare outcome measure.
CONCLUSION: Our work to date has provided better understanding of key aspects of the RA disease process as episodic, potentially disabling disease worsening even when a patient is in low disease activity. It also highlights the importance of developing ways to enhance communication between patients and clinicians and improve the ability to achieve "tight control" of disease.

Entities:  

Mesh:

Year:  2011        PMID: 21807797     DOI: 10.3899/jrheum.110401

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions.

Authors:  Ana-Maria Orbai; Serena Halls; Sarah Hewlett; Susan J Bartlett; Amye L Leong; Clifton O Bingham
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

Review 2.  Patient reported outcomes in rheumatoid arthritis clinical trials.

Authors:  Ana-Maria Orbai; Clifton O Bingham
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

3.  Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Authors:  Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2017-08-15       Impact factor: 4.666

4.  "From Where I Stand": using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ).

Authors:  Susan J Bartlett; Vivian P Bykerk; Orit Schieir; Marie-France Valois; Janet E Pope; Gilles Boire; Carol Hitchon; Glen Hazlewood; Louis Bessette; Edward Keystone; Carter Thorne; Diane Tin; Clifton O Bingham
Journal:  Qual Life Res       Date:  2022-09-08       Impact factor: 3.440

Review 5.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

Review 6.  Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.

Authors:  Arturo J Martí-Carvajal; Luis H Agreda-Pérez; Ivan Solà; Daniel Simancas-Racines
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 7.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

8.  "Stiffness has different meanings, I think, to everyone": examining stiffness from the perspective of people living with rheumatoid arthritis.

Authors:  Ana-Maria Orbai; Katherine C Smith; Susan J Bartlett; Elaine De Leon; Clifton O Bingham
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-11       Impact factor: 4.794

9.  Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis.

Authors:  Serena Halls; Emma Dures; John Kirwan; Jon Pollock; Gill Baker; Avis Edmunds; Sarah Hewlett
Journal:  Rheumatology (Oxford)       Date:  2014-09-16       Impact factor: 7.580

Review 10.  Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary.

Authors:  Susan J Bartlett; Vivian P Bykerk; Roxanne Cooksey; Ernest H Choy; Rieke Alten; Robin Christensen; Daniel E Furst; Francis Guillemin; Serena Halls; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Ana Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2015-02-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.